Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab in pediatric sickle cell disease
NCT03474965Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2018
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of crizanlizumab in sickle cell disease (SCD), sponsored by Novartis. Started Oct 2018; status: completed.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03474965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474965.